Skip to main content
BetterLife Pharma logo

BetterLife Pharma — Investor Relations & Filings

Ticker · BETR CSE Professional, scientific and technical activities
Open in API
Filings indexed 282 across all filing types
Latest filing 2025-12-18 Management Reports
Country CA Canada
Listing CSE BETR

About BetterLife Pharma

https://abetterlifepharma.com/

BetterLife Pharma is an emerging biotechnology company focused on developing and commercializing novel, patient-friendly compounds to treat neuro-psychiatric and neurological disorders, addressing significant unmet mental health needs. The company's core strategy involves revolutionizing brain health by producing non-hallucinogenic medicines. Its lead product candidate is 2-Bromo-LSD (BETR-001), a second-generation lysergic acid diethylamide (LSD) derivative. BETR-001 is designed to mimic the projected therapeutic properties of LSD, acting as a potent neuroplastogen, but without causing psychedelic effects or incurring the high regulatory hurdles associated with Schedule 1 controlled substances. BETR-001 is being developed as a potential therapy for debilitating conditions such as treatment-resistant depression, PTSD, anxiety, and cluster headaches.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Management Reports Classification · 1% confidence The document is a 'Management's Discussion and Analysis' (MD&A) report for BetterLife Pharma for the three and nine months ended October 31, 2025. It provides a detailed review of financial conditions, business operations, product development pipelines, and operational results. This document is a core component of a company's quarterly financial reporting package, which falls under the 'Management Reports' category.
2025-12-18 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Condensed Consolidated Interim Financial Statements' for BetterLife Pharma Inc. for the three and nine months ended October 31, 2025 and 2024. It contains comprehensive financial statements (Statement of Financial Position, Statement of Loss and Comprehensive Loss, Statement of Changes in Deficit, Statement of Cash Flows) and detailed notes to the financial statements. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. 9M 2026
2025-12-18 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release issued by BetterLife Pharma regarding the clinical development and advantages of their drug candidate, BETR-001. It does not constitute a formal financial report (10-K, IR), a shareholder meeting document, or a specific regulatory filing. As it is a general corporate announcement regarding business operations and product development, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate news.
2025-12-04 English
News release - English.pdf
Share Issue/Capital Change Classification · 1% confidence The document announces two primary events: the issuance of common shares and warrants in connection with debt conversion, and the resignation of a board member. While it contains management changes (MANG), the primary financial action described is the issuance of new shares to settle debt, which falls under 'Share Issue/Capital Change' (SHA). Given the document's focus on the issuance of securities, SHA is the most specific and accurate classification.
2025-11-14 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 1% confidence The document is a Form 52-109FV2 certificate (Venture Issuer Basic Certificate) certifying the interim financial report and interim MD&A. It does not contain the actual financial statements or MD&A, but is a regulatory certification form required under Canadian NI 52-109. This is not the interim report itself, earnings release, or management discussion, but a regulatory filing/certification. It therefore falls under the general fallback category for miscellaneous regulatory filings (RNS).
2025-09-27 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 1% confidence The provided document is a certification form (Form 52-109FV2) for interim filings under Canadian NI 52-109, not the interim financial report or MD&A itself. It contains the CFO’s certification of review, no misrepresentation, and fair presentation. This is a regulatory compliance filing, not the full interim report, not a summary announcement, and does not fit specialized categories like earnings release or management discussion. Therefore, it falls into the general regulatory filings category (RNS).
2025-09-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.